The NETest: The clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors Journal Article
| Authors: | Modlin, I. M.; Kidd, M.; Malczewska, A.; Drozdov, I.; Bodei, L.; Matar, S.; Chung, K. M. |
| Article Title: | The NETest: The clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors |
| Abstract: | The neuroendocrine neoplasms test (NETest) is a multianalyte liquid biopsy that measures neuroendocrine tumor gene expression in blood. This unique signature precisely defines the biological activity of an individual tumor in real time. The assay meets the 3 critical requirements of an optimal biomarker: diagnostic accuracy, prognostic value, and predictive therapeutic assessment. NETest performance metrics are sensitivity and specificity and in head-to-head comparison are 4-fold to 10-fold more accurate than chromogranin A. NETest accurately identifies completeness of surgery and response to somatostatin analogs. Clinical registry data demonstrate significant clinical utility in watch/wait programs. © 2018 Elsevier Inc. |
| Keywords: | blood; biomarker; progression; neuroendocrine tumors; pcr; transcript; netest; peptide receptor radionuclide therapy; bronchopulomary carcinoid; multigene blood analysis |
| Journal Title: | Endocrinology and Metabolism Clinics of North America |
| Volume: | 47 |
| Issue: | 3 |
| ISSN: | 0889-8529 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2018-09-01 |
| Start Page: | 485 |
| End Page: | 504 |
| Language: | English |
| DOI: | 10.1016/j.ecl.2018.05.002 |
| PROVIDER: | scopus |
| PUBMED: | 30098712 |
| PMCID: | PMC6716518 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 4 September 2018 -- Source: Scopus |
